# Nex-N2-Mini — deep_reasoning/ethical_dilemma_structured

- model_id: `nex-agi/nex-n2-mini`
- success: True  | final: 9.06 | quality: 10.0
- latency_total: 37.618s | tokens_per_second: 217.8
- input_tokens: 191 | output_tokens: 8192

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa


We need answer in Spanish. Need analyze scenario. Need maybe note "cancer detection" vague; 95% precision ambiguity? Precision vs sensitivity/specificity? Need clarify. User asks structure. Need provide stakeholders, quantitative tradeoffs, 3 options pros/cons, recommendation. We can be nuanced. Need maybe point out "precision" is not enough; false positives/negatives, prevalence, mortality benefit. Need quantify with assumptions, maybe use examples. We need not seek correct answer. Need maybe include ethical principles: beneficence, nonmaleficence, justice, autonomy, transparency. Could mention medical device regulatory, informed consent, monitoring. Need propose staged launch with safeguards, not full launch? Need compare 6 months delay. Need maybe use "salvaria vidas" but not quantify; use variables. Could create formulas and illustrative numbers. Need avoid claiming exact without data. Need include stakeholders: patients, families, clinicians, hospitals, company, board/investors, regulators, insurers, public health, underrepresented groups, data contributors, employees, society. Need quantify: 95% precision? If precision = positive predictive value, false positive rate among positives 5%. But false positives cause anxiety/unnecessary procedures. Worse for dark skin 90% precision vs 97% in light. If prevalence same, false positive burden 2x in dark skin. Need also maybe if precision means accuracy, false positive rates not directly known. Need define. For medical screening, sensitivity is critical; false negatives deadly. But prompt only gives precision. We can state limitations.

Need maybe choose recommendation: conditional/controlled launch with equity guardrails and monitoring, not wait 6 months nor uncontrolled launch. Include mitigation: limit use to approved context, clinician oversight, explicit risk stratification, no standalone diagnosis, mandatory confirmation by standard tests, enhanced review for high-risk groups, collect data, compensate? Actually can't compensate patients maybe. Offer access to standard care. Communicate uncertainty. Pause/stop criteria. Separate clinical trial or compassionate use. Need maybe mention if mortality benefit is large and current standard has poor detection, delay has expected deaths. But known bias causing disproportionate harm is serious; cannot launch as "general product" without mitigation. We can recommend "launch now under restricted, monitored rollout" with 6-month accelerated remediation. Maybe "do not deploy as autonomous diagnostic; deploy as decision-support with safeguards." If model has 95% precision and better than current standard? Need mention if no comparator.

Need quantitative tradeoffs: use example 10,000 people. Need be careful with "precision" confusion. Suppose precision (PPV) = 95%; 5% positive tests are false positives. If prevalence = 1%, 100 true cases, 9900 noncases. If precision 95%, among 105 positives 5% FP -> 5 FP and 100 TP? Wait PPV = TP/(TP+FP)=0.95. Given TP=100, FP=5.26. Sensitivity 100% in this contrived. For dark skin precision 90%, FP=11.1 for 100 TP. Difference 6 extra FPs per 100 true cases. But if sensitivity not 100, false negatives matter. Alternatively if "95% accuracy" with prevalence 1%, FPs could be many. The prompt says "5% de falsos positivos" so treat false positive rate among positives? It says "El 5% de falsos positivos" maybe false positives 5%. Let's define as "de los positivos, 5% son falsos" to align.

Need quantify expected deaths during 6 months. Need unknown. We can introduce variable M = expected deaths prevented per month if launched. Delayed deaths = 6M. If current standard mortality D_current. Launch saves S over 6 months. But biased harm: extra FPs in dark skin. Need estimate population split. Let's pick illustrative: 60% light, 40% dark? Or 70/30. Need maybe avoid assumptions; provide formula and example. Need maybe include "if 100,000 screenings per 6 months, 30% dark skin, extra FPs due to precision drop: baseline PPV 95% vs 90% => FP/TP ratio 1/19 vs 1/9; extra FP ~6.3 per 100 true cases; if dark group has 10,000 true cases, ~630 extra FPs." Need maybe quantify anxiety/procedures. Also false negative? The model "works worse" could mean precision lower; maybe more FPs or lower sensitivity. Need state if lower sensitivity, extra missed cancers are more serious. Need maybe include "precision lower can be due to lower PPV, not necessarily lower sensitivity; we need confusion matrix."

Need maybe quantify with "prevalence 1%, 100k screenings": true cases 1,000. At 95% PPV, positives = 1,053, FPs=53. At 90% PPV in dark group if prevalence same and sensitivity same? Need allocate. Suppose 30% dark = 300 cases, 700 light. Light at 95%: positives 737, FPs 37. Dark at 90%: positives 333, FPs 33. Total FPs 70. If equal precision 95% in dark: dark positives 316, FPs16; extra FPs=17 (24%). But if "dark precision 90 vs light 97" and prevalence 1% maybe FPs? Need formula. Let's compute properly.

If PPV = TP/(TP+FP). Need assume sensitivity and prevalence. For same prevalence and sensitivity, PPV changes with FP rate. Let's define false negative? If sensitivity 100%, TP=prevalence. PPV = TP/(TP+FP). So FP = TP*(1/PPV -1). For PPV 95%, FP ratio=0.0526; PPV 97%, FP ratio=0.0309; PPV 90%, FP ratio=0.1111. For 100k, prevalence 1%, true cases 1000. If 70k light (700 cases), 30k dark (300 cases). Light FPs=700*(1/0.97-1)=21.6; dark at 90% FPs=300*(1/0.90-1)=33.3; total=55. If dark at 95%, FPs=15.8; extra=17.5. If both 95%, total=52.6. If both 90%, total=111.1. If both 97%, total=32.3. This shows disparity: dark group FP rate per person: 33/30000=0.111%; light 22/70000=0.031%; dark 3.6x per person. But PPV lower 90 vs 97.

Need maybe "95% precision overall" maybe if population 70/30 and dark 90, light 97, weighted precision = 0.7*97 +0.3*90 = 95.1. Nice. So scenario matches. Need maybe use this as illustrative. Good.

Need quantify "benefit of launching now" with variable. Suppose launch saves x deaths over 6 months. Need compare to harm. If x=50 deaths, extra FPs maybe 17-33 etc. But "anxiety severe" not death. Could be procedure complications. Need maybe estimate. Need not overdo.

Need maybe talk about "expected value" includes:
- Lives saved/delayed
- False positives causing anxiety/procedures
- False negatives/misdiagnosis
- Distributional harm (racial/ethnic skin-color inequity)
- Trust/regulatory/legal risk
- Data feedback loop (if underrepresented have worse outcomes, data may worsen).
Need maybe mention "precision" is aggregate; subgroup fairness. Need maybe "no single metric can decide."

Need options:
A. Wait 6 months: no biased launch, improve model, maybe current standard. Pros: avoids known inequity, regulatory/ethical, legal; more reliable. Cons: delayed lives, opportunity cost, investors, current patients suffer, no real-world validation.
B. Unrestricted full launch now: Pros: maximum immediate access, data, revenue, lives saved. Cons: known discriminatory harm, anxiety/procedures, possible malpractice/regulatory, loss trust, worse outcomes for dark skin, ethical.
C. Controlled staged launch with equity safeguards + accelerated correction: Pros: captures lifesaving benefits while limiting harm, improves data, meets regulators, transparency, monitoring. Cons: complexity, lower short-term revenue, false reassurance if guardrails weak, need resources, operational burden, possible inequitable access if rollout criteria.

Could include D? User asks 3 options. Need maybe maybe "staged launch under IRB/clinical study" is recommendation. Need maybe maybe "limited launch only to settings where standard care is worse and with explicit consent" as C. Need maybe include "go/no-go gates": e.g., launch only if sensitivity for dark skin above threshold? But model 90% precision. Need "stop criteria": if subgroup harm exceeds threshold, pause. Need include "must-have conditions": not autonomous, confirmatory tests, clinician accountability, informed consent, reporting, data collection, equal access, independent audit. Need maybe "not enough to say '95% precision'".

Need maybe final recommendation: "No full unrestricted launch; no full wait; do a time-limited controlled deployment under medical oversight with equity guardrails, while committing to 6-month correction. If model cannot meet minimum safety/fairness thresholds or requires autonomous diagnosis, pause." Need justify: It balances lives saved vs justice; known bias can be mitigated; staged rollout reduces population-level harm; creates data to fix faster. Need maybe mention "if 6-month delay expected deaths are catastrophic (e.g., tens of thousands) and no alternative care, expand as emergency with additional safeguards; if bias harms are severe, restrict."

Need maybe include "quantitative trade-offs" maybe in a table. Let's plan Spanish answer.

Structure:
- Intro: "No hay respuesta correcta; con los datos dados, no podemos calcular valor exacto. Primero: precision no basta; need sensitivity/specificity/prevalence, current standard, prevalence by skin color, mortality." But proceed with assumptions.
- 1. Stakeholders:
- Patients with symptoms/risks: benefit from earlier detection; harmed by FPs; group-specific.
- People with dark skin/underrepresented groups: higher false positive/procedure burden; trust.
- Families/caregivers.
- Clinicians/hospitals: rely on model; workload; liability.
- Public health systems/insurers: costs.
- Company/startup: lives saved/revenue/reputation/legal.
- Board/investors.
- Regulators (FDA/EMA/etc), ethics committees, hospitals.
- Employees/data contributors.
- Society: equity/trust.
- 2. Tradeoffs quantitative:
- Define variables:
- N = people screened per period.
- p = prevalence.
- T_light/T_dark shares.
- PPV_light=97%, PPV_dark=90%, overall ~95%.
- Extra FP due to bias:
FP ratio = (1-PPV)/PPV.
For PPV 97%: 3.1 FPs per 100 TP; 90%: 11.1 per 100 TP; 95%: 5.3 per 100 TP.
- Example N=100,000, p=1%, 70k light/30k dark:
true cases: 700 light, 300 dark.
light FPs 22; dark FPs 33; total FPs 55. If dark had same 97%, dark FPs 16; extra 17 FPs (total 38). If equal 95%, total 53. This shows not huge absolute but concentrated and severe; if prevalence/cases higher or N larger, scales. Need maybe mention if precision means "accuracy", numbers differ.
- Burden distribution: dark group FPs 33/30000=0.11% vs light 22/70000=0.03%; ~3.6x per person.
- Anxiety/procedure burden: 55 unnecessary procedures per 100k; extra 17 due to bias. If 300k, extra 50; etc.
- False negatives: If 90% precision includes more FNs or lower sensitivity, missed cases may cost lives; need quantify. A small sensitivity drop can dominate. Formula: additional FNs = N_dark*p*(sens_current - sens_model) maybe. If current standard catches many. Need mention.
- Delayed launch: Let m = expected lives saved/month by early deployment. Deaths during 6 months = 6m. If m=5 -> 30; m=20 ->120. Compare to FPs/procedures. But not apples-to-apples.
- Also false positive procedures have complication risk; e.g., if biopsy complication serious 0.5%, 55 procedures ->0.28 expected serious harms per 100k; extra 17 ->0.085. If more invasive tests, higher. Need maybe not invent too much. But could illustrate.
- Ethical distribution: even if aggregate lives saved, known bias violates justice; cannot be offset purely by aggregate counts without safeguards.
- Need maybe "expected value not enough; constraints."

Need maybe "quantitative trade-off" maybe table:
Option | expected benefit | expected harms | distribution | uncertainty
- Wait: avoids bias harms but loses 6m lives; no new data.
- Full launch: saves lives now but imposes 5% FP and 2x bias; legal/regulatory.
- Controlled launch: saves maybe 60-90% of benefit if adoption lower; reduces extra FPs by 50-80% through safeguards; slower correction.

Need maybe quantify staged launch: If controlled launch initially covers 30-50% of eligible population, immediate lives saved maybe 30-50% of unrestricted. Extra FPs lower. But if high-risk groups underrepresented, bias persists. Need maybe.

Need maybe "preconditions for launch":
1. Independent clinical validation by subgroup; report sensitivity/specificity/PPV/NPV by skin tone, age, sex, cancer type, site.
2. Minimum subgroup performance thresholds: no subgroup below e.g. 90% PPV and no unacceptable sensitivity; if not, restrict.
3. Use as decision support; not standalone; confirm positives with gold standard.
4. Informed consent / disclosure: model limitation.
5. Equity monitoring: dashboards, pause thresholds.
6. Data capture and remediation: oversample underrepresented, retrain, calibrate thresholds by subgroup.
7. Clinician training and appeal process.
8. Regulatory approval/IRB.
9. Patient support for anxiety/procedures.

Need maybe "recommendation final":
"Recomiendo opción C: lanzamiento controlado y limitado, no general, con salvaguardas de equidad y monitoreo en tiempo real; al mismo tiempo, sprint 6 meses para corregir sesgo. If regulators require full validation, frame as study/compassionate use."
Justification:
- Waiting 6 months has real expected deaths; not ethically acceptable if benefit large and no current alternative.
- Full launch is unethical because known bias harms dark skin and creates avoidable procedures/anxiety; aggregate 95% hides injustice.
- Controlled launch captures most lifesaving benefit while reducing exposure, generates data, and creates accountability. It also may be more likely accepted by regulators.
- It is not "perfect"; must include stop/go criteria and independent oversight.

Need maybe "decision rule":
- Launch now if:
- expected deaths prevented in 6 months > threshold and model improves on standard of care;
- subgroup metrics meet minimum safety;
- safeguards can be implemented before launch.
- If model performance below minimum for dark skin or cannot confirm positives, do not launch.
- If delay deaths are extreme, expand rollout faster but keep safeguards.

Need maybe "pros/cons" for options:
Option 1: Esperar 6 meses.
Pros:
- Reduces known bias; more data; lower legal/regulatory; trust.
- Better calibration, subgroup performance; less anxiety/procedures.
Cons:
- Lives lost; opportunity cost; patients in need; may lose competitive edge; no real-world evidence; current standard may be worse.
Option 2: Lanzamiento masivo ahora.
Pros:
- Max impact, revenue, data, market; saves lives quickly.
Cons:
- 5% FP anxiety/procedures; disproportionate harm; potential FNs; regulatory/legal; reputational; trust collapse; inequity.
Option 3: Lanzamiento escalonado con mitigación.
Pros:
- Balanced; saves lives; controls exposure; equity; data; regulatory; transparency.
Cons:
- Operational complexity; lower immediate benefit; possible inequitable rollout if not careful; may slow iteration; requires monitoring; still some bias.

Need maybe include "pros/cons each" maybe table.

Need maybe answer in Spanish. Need maybe "No busques respuesta correcta" so phrase "mi recomendación argumentada". Need maybe "precision" issue. Need maybe avoid "cáncer" accent? Use cáncer.

Need maybe maybe "cáncer with 95% precision" is ambiguous; "precision" in ML often PPV, not "accuracy"; but lay might mean "accuracy". Need say "Asumo que 5% falsos positivos = de positivos 5% falsos; si no, numbers change." Good.

Let's think deeper: There are ethical tradeoffs. We need "best argumentada". Could discuss "expected value vs rights-based constraints." Maybe "la mejor recomendación no es maximizar vidas agregadas; there are fairness constraints." Need maybe mention "principio de no abandono" vs "justicia distributiva." Could mention "beneficencia vs justicia." Good.

Potential issue: "95% precision" overall, dark skin 90, light 97. Weighted average 95 if 70/30. Need maybe not assume 70/30? It's plausible. We can use "por ejemplo" with shares. Need maybe "si la población es 70/30, weighted 95.1". Good.

Need maybe "Falsos positivos cause anxiety severe and unnecessary procedures." Need quantify anxiety: If 55 extra? Actually total FPs. We can calculate per 100k. Need maybe "procedimientos innecesarios = 55 per 100k; extra due to bias = 17 per 100k." This is not huge but severe. If 1 million, 550 total; 170 extra. Need maybe "the absolute number is small only under prevalence 1% and PPV assumption; in high-risk population prevalence higher, FPs scale." Let's calculate high prevalence maybe 10%: 1000 true cases per 10k? For 100k, true cases 10,000. Light FPs=309; dark=1111; total=1420. If dark at 97%, dark FPs=309; extra=802. So high. But if PPV 90, FP/TP ratio 0.111, total FPs 1111 per 10k cases. That's 11% of dark group, 3% light. Need maybe mention. But keep moderate.

Need maybe "precision" as PPV depends on prevalence. In screening low prevalence, even high sensitivity/specificity can have many FPs. The 5% FP rate among positives is not same as false positive rate. If "5% de falsos positivos" means among all tests, 5% FPs, numbers differ. Need mention.

Need maybe "False negatives" maybe "if the model misses 5% of cancer cases, for 100k at 1% prevalence that's 5 missed cancers; if 6 months delay, each missed cancer may lead to death." But prompt says precision not sensitivity. Need maybe not overstate. Could say "No podemos calcular lives saved without sensitivity and prevalence." Good.

Need maybe "board asks recommendation" maybe final should be actionable. Need maybe "I would tell board: approve controlled launch under conditions; reject full launch; reject indefinite wait." Good.

Let's draft with sections.

Possible final:

```
Primero, una salvedad: "95% precision" is insufficient; I assume PPV 95 and 5% of positive calls false; if "accuracy", recalc. Need sensitivity, specificity, prevalence, mortality baseline, subgroup metrics.

1. Stakeholders
...
```

Then quantitative:
```
Variables:
N, p, q_dark, PPV_light=0.97, PPV_dark=0.90.
FP per true case = (1-PPV)/PPV.
...
Example N=100k, p=1%, q_light=.70, q_dark=.30:
...
```
Let's compute table:
Light group:
N=70,000, prevalence 1% => TP=700. PPV 97% => positives=700/0.97=721.65, FP=21.65.
Dark:
N=30,000, prevalence 1% => TP=300. PPV 90% => positives=333.33, FP=33.33.
Total positives=1055, total TP=1000, total FP=55. Overall PPV=1000/1055=94.8%, close 95.
If dark skin had 97%, dark FP=15.46; total FP=37.1. Extra FPs=17.9.
If all 95%, light FP=36.84, dark FP=15.79, total=52.63. Hmm if all 95, total similar to actual. But distribution differs: light FPs lower? Wait all 95: light FP=36.8 (0.053%), dark FP=15.8 (0.053%). Actual: light 21.6 (0.031%), dark 33.3 (0.111%). So actual aggregate total FP slightly more (55 vs 53) and concentrated in dark.
If all 90: light FP=70, dark 33.3, total 103.3.
Maybe table:
```
Scenario | Total FP | Extra vs equal 97% | Distribution
All 97%: 37 | baseline | equal
Actual 97/90: 55 | +18 | dark 60% of FPs despite 30% people
All 95%: 53 | +16 vs 97 | equal
All 90%: 103 | +66 | equal
```
But "equal 97" maybe not realistic. Use actual vs "if dark had same 97" to isolate bias. Need maybe "si la población fuera 70/30". Good.

Need maybe "expected deaths delayed":
```
If launch prevents d deaths/month, 6-month delay costs 6d. For d=10, 60 deaths; d=50, 300 deaths. That must be compared with extra FPs and procedure harms. Because d is unknown, cannot conclude from numbers alone; but it means waiting has a real expected cost.
```
Need maybe "procedure harms":
```
If 10% of FP tests lead to invasive biopsy, 55 procedures per 100k; if severe complication 1%, 0.55 expected serious harms per 100k; extra 18 ->0.18. But anxiety is non-trivial.
```
Maybe too much? Could include "not apples-to-apples" and "serious procedure risk".

Need maybe "quantitative trade-offs in terms of lives vs harms":
- Expected lives saved by launch now vs delayed = 6d.
- Expected extra bias harms = 18 extra FPs per 100k in example; if N=1M, 180 extra; if high prevalence 10%, 1,800 extra.
- If each avoided death has high moral/legal weight, maybe launch. But known bias means need mitigate.

Need maybe "threshold reasoning":
```
Decision threshold: If 6d is large and safeguards reduce extra FPs by e.g. 70%, controlled launch is justified. If d is small or bias causes more severe outcomes (e.g., more false negatives), wait.
```
Need maybe "stop criteria":
- If subgroup PPV/sensitivity below pre-set threshold or harms exceed threshold, pause.
- If independent audit finds disparity, stop.

Need maybe "recommendation final":
```
Approve Option 3: staged launch. Conditions:
1. Clinical governance: IRB/regulator, physician oversight, consent, no autonomous diagnosis.
2. Equity: subgroup validation, thresholds, calibration, oversampling dark skin, retraining within 6 months, publish metrics.
3. Operational: confirm positives with standard tests; triage to minimize invasive procedures; patient support; monitor anxiety/procedure rates.
4. Data: capture outcomes by subgroup; feedback loop.
5. Communication: transparent limitations; no marketing overclaim.
```
Need maybe "if cannot implement safeguards, do not launch; if lives at risk extremely high, expand rollout faster under same safeguards."

Need maybe "what to tell board":
```
No: uncontrolled launch. No: waiting silently. Yes: controlled launch with explicit fairness constraints and time-bound remediation.
```
Need maybe "pros/cons" table perhaps before recommendation.

Need maybe "stakeholders affected" maybe in bullet list with "direct/indirect." Need include "skin color" maybe sensitive attribute; avoid treating skin color as biological only; include socio-demographic proxies. But okay.

Need maybe "regulators" include FDA/CE/ANMAT etc. "Board" maybe stakeholders.

Potential challenge: "precision" in Spanish maybe "precisión" can mean accuracy; prompt says "El 5% de falsos positivos" but "precision 95" maybe they mean "accuracy." Need maybe in final say "Asumo que precision = PPV; si no, the calculation changes; but conclusion same: need subgroup validation." Good.

Need maybe "procedures unnecessary" not just FPs but false positives cause anxiety severe. Need maybe "false positives can be worse for dark skin due to bias." Good.

Let's consider if there is a better recommendation: "Wait 6 months" might be ethically justified because launching with known bias violates justice; but prompt says launch saves lives. Need maybe "best argumentada" likely answer: staged launch with safeguards. Could maybe mention "if model has known bias, you can adjust threshold by skin type to equalize false positive rates" but careful: equalizing may reduce sensitivity/precision; but can. Need maybe include "calibration and threshold adjustment." Good.

Need maybe "quantitative trade-offs" maybe include "expected harm if not launch" with formula:
- Lives lost from delay: \(6 \times \Delta \text{mortality}\times \text{eligible patients}\).
- False positives: \(FP = N \times p \times (1-\text{PPV})/\text{PPV}\).
- Extra FPs due to bias: \(N_d p [(1/0.90-1)-(1/0.97-1)]\).
Let's compute formula:
\( (1/0.90 -1) - (1/0.97 -1) = 0.1111 - 0.0309 = 0.0802 \) FPs per true case. If N_dark=30k p=1%, true dark cases=300, extra FPs=24.1? Wait 300*0.0802 =24.1. But earlier extra vs all 97: actual dark FP 33.3 - all 97 dark FP 15.5 =17.8. Why difference? Because if all 97, light FPs decrease too; extra total vs all 97 is 17.8. Formula for dark group only is 17.8? Let's recompute: 1/0.90 -1 = 0.111111; 1/0.97 -1 = 0.030928; difference = 0.080183. times 300 = 24.05. But earlier actual dark FP = 33.333; all 97 dark FP = 300/0.97 -300 = 15.464; difference=17.869. Why? Because 300/0.90 -300 = 333.333-300=33.333. 300/0.97 -300 = 309.278-300=15.278? Wait 300/0.97 =309.278, minus 300=9.278, not 15.464. I made mistake. Let's recalc:
Light: 700/0.97=721.649, minus 700=21.649.
Dark: 300/0.90=333.333, minus 300=33.333.
Total actual FP=54.982.
All 97: light FP=21.649, dark FP=9.278, total=30.927.
Extra vs all 97 =24.055. Yes. I earlier said 15.464 erroneously. All 95: light FP=36.842, dark=15.789, total=52.632. All 90: light FP=70, dark=33.333, total=103.333. Good.
Need update numbers:
- Actual total FP 55.
- Extra FPs if dark were 97: 24 per 100k.
- Dark FPs per person 0.111%; light 0.031%; 3.6x.
- Dark share of FPs actual: 33/55=61%, despite 30% population. Good.
- If all 95: total 53, extra vs all 97:21.7.
Need maybe table:
```
Caso | FPs totales por 100k | Extra vs dark 97 | Distribución
97 light / 90 dark | 55 | +24 vs all 97 | 61% in dark group
all 97 | 31 | baseline | equal
all 95 | 53 | +22 | equal
all 90 | 103 | +72 | equal
```
This is better. Need maybe mention "with prevalence 1%". Good.

But wait "overall precision 95" if light 97, dark 90 and shares 70/30, weighted precision 95.1. Good.

Need maybe "If prevalence 10%, total FP = 550 actual, extra 240; dark share 61%." Good mention scaling.

Need maybe "If N=1M, actual FPs 550; extra bias FPs 240; anxiety severe. If 10% prevalence, 5,500 actual; extra 2,400." Good.

Need maybe "procedures unnecessary" if all FPs lead to procedure; maybe not all. Use "si todos generaran un procedimiento..." But in real screening, false positives may lead to further tests, not all biopsies. Good.

Need maybe "expected lives saved" formula:
Let \(d\) = deaths averted per month. If d=10, 60 deaths; if d=100, 600. Need maybe "the expected lives saved likely dwarfs the extra FPs numerically; but lives vs procedures/anxiety not commensurate." Good.

Need maybe "false negative with 90% precision" maybe "if lower precision due to more false negatives, e.g., 5% of cases missed in dark group, with 300 cases per 100k, 15 missed cancers; if 10% mortality in 6 months, 1.5 deaths." But maybe not necessary. But to be quantitative, could include "need sensitivity; if false negatives increase from 3% to 10%, extra missed cases = N_dark*p*0.07 =2.1 per 100k; at 10% 21; etc." Hmm maybe too much. Maybe state "If the 90% precision is mainly more FPs, harms are anxiety/procedure; if it is more FNs, harm is missed cancer/death. We need confusion matrix." This is important. Could maybe include "the option of launch must be based on sensitivity; a model with high PPV but low sensitivity can miss cancers." But prompt says "detect cancer with 95% precision" maybe not enough. We can say "I would demand sensitivity by subgroup before launch."

Need maybe "board" maybe "recommendation final with justification" not necessarily too long. Desired overwordiness medium. Need maybe moderate length.

Let's think of edge cases:
- If the model is "precision" not "accuracy", PPV 95 means only 5% of positive calls are false. That is high. But cancer screening false positives can still be many. If "precision" means accuracy, then with prevalence 1%, a model can be 95% accurate by saying everyone negative, not useful. So we must emphasize. Good.

Need maybe "quantitative tradeoff with false positives severe" maybe "5% of positives" vs "5% of all tests" difference. If 5% of all tests false positive, with prevalence 1%, PPV terrible (TP maybe?). But prompt says 5% FPs. We can mention "If 5% de todos los tests son FPs, the model is not acceptable for screening; PPV would be low." Maybe not necessary but helpful.

Need maybe "stakeholders affected" maybe "people of dark skin" not only skin tone but "racial/ethnic groups correlated with skin tone; dataset contributors." Good.

Need maybe "procedures unnecessary" "anxiety severe" "procedures can include biopsies, imaging, surgeries; risk physical harm and financial costs." Good.

Need maybe "launch now save lives" "but bias known." Need maybe "we need to compare with current standard of care; if current standard already detects cancers in dark skin equally, model may not save lives for them; if current standard is worse, launch could reduce disparity." Good. Mention in stakeholders/tradeoff.

Potential final format:

```
### 0. Premisa y limitación
...
### 1. Stakeholders
...
### 2. Trade-offs cuantitativos
...
### 3. Opciones
| Opción | Pros | Contras | Cuándo tendría sentido |
...
### 4. Recomendación final
...
```

Need maybe "No busques respuesta correcta" so "Mi recomendación no es universal; depende de m and subgroup metrics." Good.

Let's craft final in Spanish.

Need maybe be precise in "precision" assumption:
"Para poder hacer números, asumiré que '95% de precisión' = PPV/precision: de los pacientes a los que el modelo dice 'cáncer', 5% realmente no lo tienen. Si se refiere a accuracy, no se puede decidir sin prevalencia." Good.

Quantitative:
```
FP por 100 casos verdaderos:
PPV 97% -> 3.1 FPs
95% -> 5.3
90% -> 